Leukemia Clinical Trials

Showing 321-340 of 8,366 trials

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

NCT07038369

This is a Phase 1, open-label study to evaluate the safety and tolerability of ATV-1601 administered orally in adults with AKT1 E17K-mutant, advanced solid tumors and also in HR+/HER2- advanced and metastatic breast cancer, with or without fulvestrant.

Advanced Solid TumorsBreast CancerBreast Carcinoma+24 more

Atavistik Bio, Inc134 participantsStarted Jul 2025

Los Angeles, California, United States • Lake Mary, Florida, United States • Boston, Massachusetts, United States +5 more locations

RECRUITING

Association Between Intake of Psychotropic Medications and Risk of Falls in Older Adults

NCT07112573

The aim of the study is to assess the association between intake of psychotropic medications and increased risk of falls in older adults discharged from Ain Shams University Geriatric Hospital as a primary outcome and incident fractures that may occur as a secondary outcome of such fall.

Falls (Accidents) in Old AgePsychotropic Drugs

Ain Shams University398 participantsStarted Jul 2025

Cairo, Abbassia, Egypt

Enrolling By Invitation

Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance

NCT07122882

Currently, tyrosine kinase inhibitor (TKI) remains the standard of care for oncogene-driven non-small cell lung cancer (NSCLC). However, almost all oncogene-driven NSCLCs would develop acquired resistance against TKI in clinical practice. Therefore, understanding the molecular mechanisms underlying the acquired resistance is a critical issue in lung cancer. Based on the literature, acquired resistance mechanism against EGFR TKI includes EGFR secondary mutation (T790M, C797X, L792X, G796X, L718Q, and exon 20 insertions), MET amplification, HER2 amplification, acquired gene fusions, and other complex alterations. From the perspective of mutagenesis, the acquired resistance against TKI may be associated with APOBEC mutational processes, kataegis, chromothripsis, extrachromosomal DNA (ecDNA), and the interaction among them. However, still 30% to 50% of oncogene-driven NSCLCs had no identified mechanism attributed to the acquired resistance. Previous studies mostly used targeted-gene sequencing, which may overlook some structural variation and the transcriptomic dynamics. This study aims to investigate the genomic alterations, mutational processes, and the transcriptomic landscape underlying the acquired resistance using integrated genomics.

Oncogene-addicted Non Small Cell Lung CancerEGFR MutationALK Fusion-positive Solid or CNS Tumors+10 more

Chang Gung Memorial Hospital40 participantsStarted Sep 2025

Taoyuan District, Taiwan

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

Association Between Intake of Psychotropic Medications and Risk of Falls in Older Adults

Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance

Related Searches

Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer

Special Drug Use Observational Study of Xolair in Patients With Severe to Most Severe Seasonal Allergic Rhinitis Aged ≥ 12 Years and < 18 Years Whose Symptoms Were Inadequately Controlled Despite to Conventional Therapies

Small Bowel Capsule Endoscopy in Lynch Syndrome

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL

A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

SYS6090 Combination Therapy in Advanced Lung Cancer

Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer